7月9日,复星医药(600196/02196)发布公告,控股子公司药品临床试验进展情况。公告指出,该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®(芦沃美替尼片)用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物,属于MEK1/2选择性抑制剂。截至2025年5月,该药品的累计研发投入约为6.07亿元(未经审计)。目前,该药品在中国境内已上市并获批两项...
Source Link7月9日,复星医药(600196/02196)发布公告,控股子公司药品临床试验进展情况。公告指出,该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®(芦沃美替尼片)用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物,属于MEK1/2选择性抑制剂。截至2025年5月,该药品的累计研发投入约为6.07亿元(未经审计)。目前,该药品在中国境内已上市并获批两项...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.